Use of Intravenous Immunoglobulins and Systemic Corticosteroids in Patients with Toxic Epidermal Necrolysis: Experience of a Hospital in Mexico City.

Autor: Barrera-Ochoa CA; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México. Electronic address: cabaoch@gmail.com., Marioni-Manríquez S; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México., Cortázar-Azuaje AM; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México., Quijada-Ucelo ZM; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México., Saba-Mussali AJ; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México., Vega-Memije ME; División de Dermatología, Hospital General Dr. Manuel Gea González, Ciudad de México, México.
Jazyk: English; Spanish; Castilian
Zdroj: Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2022 Mar; Vol. 113 (3), pp. 294-299. Date of Electronic Publication: 2021 Nov 10.
DOI: 10.1016/j.ad.2021.08.008
Abstrakt: Toxic epidermal necrolysis is the most serious mucocutaneous adverse drug reaction. Multidisciplinary treatment and withdrawal of the causative drug are key to reducing mortality. Few studies have analyzed the use of systemic corticosteroids and intravenous immunoglobulins (IVIG) in patients with toxic epidermal necrolysis in Latin America. We describe our experience with 6 cases treated at a dermatology referral hospital in Mexico City. None of the patients died or developed complications in the short or medium term. The most widely used regimen was a combination of IVIG 1 g/kg for 3 to 5 days and methylprednisolone 1 g for 3 to 5 days. Mean hospital stay was 14.8 days. The combined use of systemic corticosteroids and IVIG seems to be a safe treatment option for patients with toxic epidermal necrolysis.
(Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE